Clinical Observation In Advanced Non Small Cell Lung Cancer Treating With Microwave Ablation Combined With Chemotherapy

Objective:The aim of the study was to determine survival benefit and the safety of the microwave ablation (MWA)/chemotherapy combination compared with chemotherapy alone.Methods:We retrospectively reviewed and analysis 73 cases of III B, IV stage peripheral non small cell lung cancer patients, they were divided into the observation group and the control group. Thirty-eight patients enrolled in the observation group were treated with CT guided microwave ablation, and then they were given a chemotherapy program one week after operation which is the plan of nedaplatin combination with docetaxel. The other thirty-five patients divided into the control group were only given the same chemotherapy program. We evaluated the recent curative effect of microwave ablation according to the modified RECIST solid tumor evaluation criteria, and we also observed the complications and adverse reaction. We have followed up all the patients and compared two groups of patients with KPS score, OS (overall survival) and PFS (progression free survival). Results:The short term effect:in the observation group (38 cases) three patients achieved a CR, nine patients achieved a PR, and eighteen patients exhibited SD, the total effective rate was 31.57%(12/38), the disease control rate was 78.94% (30/38). In the chemotherapy group (35 cases) one patient achieved a CR, seven patients achieved a PR, and ten patients exhibited SD, the total effective rate was 22.85%(8/35), the disease control rate was 51.42%(18/35). It has significance difference between the statistical of the two groups (P＜0.05). The major complications of the combined group were pneumothorax, nine patients had occurred pneumothorax after ablation, no needle track implantation metastasis have been founded, nor ablation related deaths until 30 days after ablation. After a median follow-up of 19 months, the OS (overall survival) in the two groups is 19.8 months and 16.9 months, respectively. It has no statistical difference between with the two groups (P>0.05). And the PFS is 10.3 months and 4.9 months, respectively. It is significant between the difference of the two groups (P<0.05).Conclusion:Microwave ablation (MWA)/chemotherapy combination compared with chemotherapy group improved PFS in patients with advanced NSCLC significantly, without increasing chemotherapy adverse events.